Medicare Coding Change For Biosimilars Could Save $65bn, Firms Say
Biopharma manufacturers, payers and other stakeholders strongly support changing an Obama-era policy for reimbursing biosimilars under Medicare Part B in comments to the Centers for Medicare and Medicaid Services.
You may also be interested in...
Exclusive contracts for J&J's Remicade have posed challenges for Pfizer's Inflectra in the commercial insurance market, the biosimilar's maker said during its second quarter earnings call.
Launch of a second infliximab biosimilar by Merck triggers Medicare's controversial biosimilars reimbursement policy for the first time.
Policy of paying for all biosimilars referencing the same drug at one blended rate is under review, to the relief of product developers and other stakeholders.